Skip to main content

Pyxis Oncology, Inc 8-K, filed Nov 19, 2026

Pyxis Oncology, Inc. (PYXS)

8-K 2026-11-19 For: 2026-11-18
View Original
Added on November 19, 2026

About this 8-K

Pyxis Oncology, Inc filed this 8-K on November 19, 2026, reporting on events of November 18, 2026.

Pyxis Oncology reported updated results from its ongoing global Phase 1 monotherapy study of micvotabart pelidotin (MICVO) in patients with second-line and beyond recurrent/metastatic head and neck squamous cell carcinoma. As of October 14, 2026, among 33 efficacy evaluable patients, the confirmed objective response rate was 39% and median progression-free survival was 6.7 months. The company plans to advance MICVO into a global Phase 3 trial, planned to initiate in mid-2027. AI summary

Items reported

  • Item 7.01: Regulation FD disclosure
  • Item 8.01: Other events